US equities |
MU $1,032.50 ▼-5.10% NVDA $230.09 ▼-3.11% SNDK $1,599.45 ▼-5.49% AMD $614.37 ▼-4.88% INTC $106.04 ▼-6.26% SPCX $161.62 ▼-3.57% META $719.03 ▼-0.32% MSFT $521.43 ▼-1.57%
FinancialContent

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.540 -0.070 (-4.35%)
Delayed Quote Updated: 3:07 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediciNova, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
MediciNova to Participate in the Maxim Growth Summit
From MediciNova, Inc.
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat 
From MediciNova, Inc.
Via GlobeNewswire
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
From MediciNova, Inc.
Via GlobeNewswire
Unusual volume stocks in Monday's session ↗
Via Chartmill
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
MediciNova to Participate in Two Investor Conferences in September
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova CEO Provides Shareholder Update
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Participate at the 38th Annual ROTH Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
2026 New Year’s Greetings from the CEO
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Message from the CEO to MediciNova Shareholders
Strengthening MN-001’s Scientific Foundation and Clinical Outlook 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
From MediciNova, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Monday's session ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
These stocks have an unusual volume in today's session ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? ↗
MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >